Entrada Therapeutics Inc (TRDA) - Total Assets
Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) holds total assets worth $412.90 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Entrada Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Entrada Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Entrada Therapeutics Inc (TRDA) market capitalisation for the company's overall valuation and market capitalisation.
Entrada Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Entrada Therapeutics Inc's total assets of $412.90 Million consist of 83.6% current assets and 16.4% non-current assets. Review Entrada Therapeutics Inc (TRDA) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.2% |
| Accounts Receivable | $3.68 Million | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Entrada Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Entrada Therapeutics Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Entrada Therapeutics Inc's current assets represent 83.6% of total assets in 2024, a decrease from 95.6% in 2019.
- Cash Position: Cash and equivalents constituted 19.2% of total assets in 2024, down from 92.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Entrada Therapeutics Inc Competitors by Total Assets
Key competitors of Entrada Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Entrada Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.08 | 6.59 | 11.89 |
| Quick Ratio | 14.08 | 6.64 | 11.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $314.24 Million | $394.73 Million | $36.59 Million |
Entrada Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Entrada Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.18 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | 12.2% |
| Total Assets | $526.32 Million |
| Market Capitalization | $263.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Entrada Therapeutics Inc's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Entrada Therapeutics Inc's assets grew by 12.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Entrada Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Entrada Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $526.32 Million | +12.18% |
| 2023-12-31 | $469.19 Million | +86.15% |
| 2022-12-31 | $252.06 Million | -17.58% |
| 2021-12-31 | $305.83 Million | +602.63% |
| 2020-12-31 | $43.53 Million | +138.66% |
| 2019-12-31 | $18.24 Million | -- |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a varie… Read more